Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes? | Zendy

Pranita D. Tamma | Zendy; Virginia Pierce | Zendy; Sara E. Cosgrove | Zendy; Ebbing Lautenbach | Zendy; Anthony Harris | Zendy; Divya Rayapati | Zendy; Jennifer Han | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?

Author(s) -

Pranita D. Tamma,

Virginia Pierce,

Sara E. Cosgrove,

Ebbing Lautenbach,

Anthony Harris,

Divya Rayapati,

Jennifer Han

Publication year - 2018

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofy139

Subject(s) - medicine , ceftriaxone , breakpoint , antibiotics , microbiology and biotechnology , biology , chromosomal translocation , biochemistry , chemistry , gene

Our findings suggest that patient outcomes are similar when receiving ceftriaxone vs extended-spectrum agents for the treatment of bloodstream infections with ceftriaxone MICs of 2 mcg/mL. This warrants consideration of adjusting the ceftriaxone susceptibility breakpoint from 1 to 2 mcg/mL, as a relatively small increase in the antibiotic breakpoint could have the potential to limit the use of large numbers of extended-spectrum antibiotic agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research